Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 2/20 | 0.31 |
| ▸ | FPR2 | P25090 | 4/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19901966 | 0.91 | IDO1 (0.35) | IDO1KMT2AACACBFPR2ALOX5AP | |
| SCHEMBL12821099 | 0.88 | ACACB (0.35) | IDO1KDM1AACACBFPR2EGFR | |
| SCHEMBL14922531 | 0.85 | KDM1A (0.41) | KDM1AFPR2LMNAHTTPTGDR2 | |
| SCHEMBL12823809 | 0.83 | CNR2 (0.38) | CNR2ALOX5APFEN1 | |
| SCHEMBL10303398 | 0.82 | TP53 (0.34) | KMT2AKDM1AACACBFPR2LMNA | |
| SCHEMBL12223403 | 0.82 | TP53 (0.34) | KMT2AKDM1AACACBFPR2LMNA | |
| SCHEMBL11940774 | 0.81 | MAPT (0.40) | KDM1AFPR2LMNAHTTPTGDR2 | |
| SCHEMBL12822791 | 0.81 | CNR2 (0.40) | CNR2ALOX5APFEN1 | |
| SCHEMBL12823527 | 0.81 | CNR2 (0.40) | CNR2ALOX5APFEN1 | |
| SCHEMBL1242545 | 0.81 | KDM1A (0.33) | IDO1KMT2AKDM1AACACBALOX5AP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902905-B2 | Liquid crystal composition and liquid crystal display including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-02-27 | — | — | US | disclosed |
| US-9902905-B2 | Liquid crystal composition and liquid crystal display including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-02-27 | — | — | US | disclosed |
| US-9580652-B2 | Liquid crystal compound, liquid crystal composition including the same and liquid crystal display including the liquid crystal composition | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-02-28 | — | — | US | disclosed |
| US-9580652-B2 | Liquid crystal compound, liquid crystal composition including the same and liquid crystal display including the liquid crystal composition | SAMSUNG DISPLAY CO., LTD. (KR) | 2017-02-28 | — | — | US | disclosed |
| US-20160362604-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-12-15 | — | — | US | disclosed |
| US-20160362604-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-12-15 | — | — | US | disclosed |
| US-20160083653-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME AND LIQUID CRYSTAL DISPLAY INCLUDING THE LIQUID CRYSTAL COMPOSITION | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
| US-20160083653-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION INCLUDING THE SAME AND LIQUID CRYSTAL DISPLAY INCLUDING THE LIQUID CRYSTAL COMPOSITION | SAMSUNG DISPLAY CO., LTD. (KR) | 2016-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362604-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY INCLUDING THE SAME | LEF1, CCR3, AFF1 | IDO1 3121/4885KMT2A 2882/4885KDM1A 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.